TScan Therapeutics to Present at Jefferies Global Healthcare Conference

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment, has announced its upcoming presentation at the Jefferies Global Healthcare Conference. This event will take place at the Marriott Marquis in New York on Wednesday, June 5, 2024, at 11:00 a.m. Eastern Time. Interested parties can view a live webcast of the presentation on the "Events and Presentations" section of TScan's website. An archived replay will be accessible on the website for 90 days post-event.

TScan Therapeutics is dedicated to advancing TCR-T therapies to aid cancer patients. The company's leading TCR-T candidates, TSC-100 and TSC-101, are currently in development to treat hematologic malignancies by preventing relapse after allogeneic hematopoietic cell transplantation. Additionally, TScan is working on TCR-T candidates aimed at treating various solid tumors.

A significant aspect of TScan's innovation is its ImmunoBank, a repository containing therapeutic TCRs that target a wide range of antigens and correspond to multiple HLA types. This resource enables the creation of personalized multiplex therapeutic TCR-Ts for patients combating different cancers.